Sonrotoclax + Zanubrutinib Well Tolerated Deep Responses TN-CLL/SLL [ASH 2023]

In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology, investigates a combination therapy for treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL) patients. The study focuses on the safety and efficacy of combining Sonrotoclax, a second-generation BCL2 inhibitor, with Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor. Preliminary results suggest outcomes, … Continue reading Sonrotoclax + Zanubrutinib Well Tolerated Deep Responses TN-CLL/SLL [ASH 2023]